In this study, fluticasone furoate (FF) and vilanterol (VI) in different dose combinations
(50/25mcg, 100/25mcg and 200/25mcg) will be administered from a single dry powder device to
evaluate the PD, PK, safety and tolerability of the combination in healthy Chinese subjects.
The information gathered will be used as a support of the clinical development program of the
fixed dose combination of FF/VI inhalation powder in Chinese population.